NeuroMetrix (NURO) Stock Price, News & Analysis

Company Overview

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

Key Stats

• Today's Range: $3.80 to $4.01
• 50-Day Range: $3.55 to $4.58
• 52-Week Range: $2.66 to $4.73
• Volume: 28,343 shs
• Average Volume: 25,952 shs
• Market Capitalization: $7.97 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NeuroMetrix Stock Analysis - MarketRank™

NeuroMetrix scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for NeuroMetrix.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of NeuroMetrix is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NeuroMetrix is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NeuroMetrix has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.13% of the float of NeuroMetrix has been sold short.

Short Interest Ratio / Days to Cover

NeuroMetrix has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NeuroMetrix has recently decreased by 26.65%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NeuroMetrix does not currently pay a dividend.

Dividend Growth

NeuroMetrix does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.13% of the float of NeuroMetrix has been sold short.

Short Interest Ratio / Days to Cover

NeuroMetrix has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NeuroMetrix has recently decreased by 26.65%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.64

News Sentiment

NeuroMetrix has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for NeuroMetrix this week, compared to 0 articles on an average week.

MarketBeat Follows

Only 1 people have added NeuroMetrix to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NeuroMetrix insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.30% of the stock of NeuroMetrix is held by insiders.

Percentage Held by Institutions

Only 19.40% of the stock of NeuroMetrix is held by institutions.

NURO Stock Analysis - Frequently Asked Questions

How have NURO shares performed this year?

NeuroMetrix's stock was trading at $3.60 at the start of the year. Since then, NURO stock has increased by 8.3% and is now trading at $3.90.
View the best growth stocks for 2024 here.

How were NeuroMetrix's earnings last quarter?

NeuroMetrix, Inc. (NASDAQ:NURO) issued its quarterly earnings data on Tuesday, November, 5th. The medical device company reported ($0.75) earnings per share for the quarter. The medical device company earned $0.59 million during the quarter. NeuroMetrix had a negative net margin of 203.71% and a negative trailing twelve-month return on equity of 42.56%.

When did NeuroMetrix's stock split?

NeuroMetrix shares reverse split on Wednesday, November 22nd 2023. The 1-8 reverse split was announced on Monday, November 20th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

How do I buy shares of NeuroMetrix?

Shares of NURO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of NeuroMetrix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroMetrix investors own include AMC Entertainment (AMC), NIO (NIO), Digital World Acquisition (DWAC), Meta Platforms (META), Advanced Micro Devices (AMD), Pfizer (PFE) and Tesla (TSLA).

Company Calendar

• Last Earnings: 11/05/2024
• Today: 12/22/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NURO
• CUSIP: N/A
• CIK: 1289850
• Web: www.neurometrix.com
• Phone: (781) 890-9989
• Fax: 302-636-5454
• Employees: 20
• Year Founded: 1996

Profitability

• EPS (Most Recent Fiscal Year): ($4.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-6,530,000.00
• Net Margins: -203.71%
• Pretax Margin: -203.69%
• Return on Equity: -42.56%
• Return on Assets: -39.26%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.88
• Quick Ratio: 12.70

Sales & Book Value

• Annual Sales: $3.77 million
• Price / Sales: 2.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $13.18 per share
• Price / Book: 0.30

Miscellaneous

• Outstanding Shares: 2,043,000
• Free Float: 1,894,000
• Market Cap: $7.97 million
• Optionable: Not Optionable
• Beta: 2.18